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ABSTRACT  31	
Using a mouse retroviral model, we have shown that monoclonal antibody (mAb)-based 32	
immunotherapy can induce life-long endogenous protective immunity (vaccine-like effects). This 33	
observation has potentially important consequences for treating life-threatening human viral 34	
infections. Here, we investigated the role of neutrophils in this effect. Neutrophils are innate immunity 35	
effector cells with well-established microbe-killing activities that are rapidly mobilized upon infection. 36	
They are also emerging as orchestrators of innate and adaptive immunities. However, their 37	
immunomodulatory activity during antiviral mAb immunotherapies has never been studied. Our data 38	
reveal that neutrophils have an essential role in immunotherapy-induced immune protection of 39	
infected mice. Unexpectedly, neutrophils have a limited effect in controlling viral propagation upon 40	
passive immunotherapy administration, which is mostly mediated by natural killer cells (NKs). 41	
Instead, neutrophils operate as essential inducers of a potent host humoral antiviral response. Thus, 42	
neutrophils play an unexpected key role in protective immunity induction by antiviral mAbs. Our 43	
work opens new approaches to improve antiviral immunotherapies as they suggest that preserving 44	
neutrophil functions and counts might be required for achieving mAb-induced protective immunity.  45	
 46	47	
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INTRODUCTION 48	
Neutralizing monoclonal antibodies (mAbs) are now considered as a potential therapeutic approach for 49	
the prevention and treatment of chronic and acute viral infections, including newly emerging viral 50	
infections (1). In recent years, there has been a dramatic increase in the development of new mAbs 51	
with improved neutralizing activity (1–14). Notably, in addition to anti-respiratory syncytial virus 52	
(RSV) mAb used to treat infant respiratory disease, several mAbs directed against human 53	
cytomegalovirus, human immunodeficiency- (HIV), influenza-, Ebola- and rabies virus are currently 54	
engaged in promising clinical trials (1, 3, 9, 14). While the direct effects of antiviral mAbs on viral 55	
propagation have been studied extensively, little attention has been paid to their potential 56	
immunomodulatory effects until recently (10, 15, 16).  57	
Using a mouse model of persistent retroviral infection, the erythroleukemia induced by the Murine 58	
Leukemia Virus FrCasE, we have shown that treatment of infected mice with a highly neutralizing 59	
mAb can induce life-long protective immunity (vaccine-like effects) (see 10). This observation may 60	
have major therapeutic implications for humans. Indeed, increased antiviral immune responses after 61	
mAb treatments were recently observed in preclinical models of HIV, RSV and henipavirus infections 62	
(see 10). Moreover, passive immunotherapy with broadly neutralizing mAbs stimulated antiviral 63	
antibody responses in HIV-1-infected patients (14). Similarly, vaccine-like effects have also been 64	
documented in preclinical models of cancer immunotherapies (17–19), as well as in clinical trials 65	
using anti-CD20, anti-EGFR or anti-HER2 mAbs (20–23). Yet, neither the mechanisms at play nor the 66	
possible long-term protective consequences have been addressed in such clinical trials. 67	
In humans, technical-, ethical- and cost limitations strongly limit investigations. Instead, 68	
immunocompetent animals offer the possibility to identify the cellular and molecular actors of 69	
antiviral mAb-induced vaccine-like effects. The FrCasE-induced erythroleukemia is a model system 70	
permitting extensive analysis of the endogenous immune response after passive mAb-based 71	
immunotherapy under conditions of both chronic infection and pathological development. We found 72	
that a 5-day treatment of FrCasE-infected mice with the neutralizing mAb 667 (an IgG2a recognizing 73	
the retroviral envelope glycoprotein; Env) shortly after infection provides long-lasting (> 1 year) 74	
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protective antiviral immunity of the Th1 type with enhanced IgG2a humoral- and cytotoxic T cell 75	
(CTL) responses and reduced regulatory T-cell activity (24–29). The immunomodulatory action of 76	
mAb 667 depends on its ability to interact with receptors for IgGs (FcgR). Notably, immune 77	
complexes (ICs) formed between the administered mAb and viral determinants enhance antiviral CTL 78	
responses through FcgR-mediated binding to dendritic cells (DCs) (27). 79	
Importantly, IC-FcgR interactions concern several FcgR-bearing innate effector cells other than DCs, 80	
including neutrophils that are rapidly recruited at sites of infections. While they have long been 81	
viewed as simple and direct scavengers of extracellular pathogens, there is recent evidence that 82	
neutrophils can be key cells in the orchestration of innate and adaptive immunity via the interaction 83	
with different myeloid and lymphoid cells and the modulation of their functions (30, 31). However, 84	
their role in antiviral immunity is still largely unknown. Indeed, most investigations have studied 85	
neutrophil functions in viral pathogenesis or in the control of viral propagation through their effector 86	
functions, i.e. phagocytosis, reactive oxygen species production, neutrophil extracellular traps 87	
formation, etc. (32, 33). In contrast, the immunomodulatory properties of neutrophils have been poorly 88	
studied in viral infections and not addressed in the context of antiviral immunotherapies. 89	
Here, we used the FrCasE model to address the general question of neutrophils participation in the 90	
induction of protective immunity by antiviral mAbs. We found that they are essential for the 91	
protection of infected, 667-treated mice. Unexpectedly, and unlike NKs, neutrophils had a limited 92	
effect on viral propagation control. Instead, their protective effect relied on their capacity to induce 93	
potent humoral responses due to the acquisition of B-cell-helper activity upon mAb treatment. Our 94	
findings should facilitate improved design of mAb-based antiviral therapies as they suggest that 95	
preserving neutrophil functions and counts might be required for achieving optimal protection by 96	
mAb.  97	
98	
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RESULTS 99	
Neutrophils are necessary for protection of infected mice by antiviral mAb without affecting viral 100	
propagation. We first addressed neutrophil mobilization in FrCasE-infected mice with, or without, 667 101	
mAb treatment (infected/treated vs infected/non-treated). Passive immunotherapy was administered on 102	
the same day after establishment of viral infection (27) (Figure 1A, upper part) and at days 2 and 5 p.i. 103	
Age-matched naive mice were used as controls. Neutrophil recruitment was assessed in the spleen, one 104	
of the most viremic organs, at day 8 p.i, when viral replication is maximal in infected/non-treated mice 105	
(27). Neutrophil abundance in infected/treated mice was comparable to that observed in naive mice, 106	
whereas it was significantly higher in infected/non-treated animals (Figure 1B). Interestingly, this 107	
increased neutrophil frequency was associated with a higher percentage of spleen infected cells 108	
(Figure 1C), as assessed by flow cytometry using the H34 antibody (recognizing a Gag protein epitope 109	
expressed on the surface of FrCasE-infected cells) (34–36).  110	
Next, we assessed the role of neutrophils in the control of viral propagation, as well as in the 111	
protection against leukemia in infected mice, with or without 667 mAb treatment. To this end, 112	
neutrophils were depleted by administering a mAb (1A8) directed to their specific Ly6G cell surface 113	
marker (37, 38) or an isotype control mAb (2A3). Depletion started 1 day before infection (Figure 1A, 114	
lower part), was efficient and specific (Supplemental Figure 1), and was maintained for 21 days, i.e. 115	
the time necessary to eliminate the therapeutic 667 mAb (27). Neutrophil elimination accelerated 116	
disease development in infected/non-treated mice and drastically reduced protection provided by 667 117	
to infected mice (Figure 1D). We next assessed viral propagation in the different groups of mice. In 118	
infected/non-treated animals, neutrophil depletion (Figure 2A) was associated with a significant 119	
increase in the percentage of infected spleen cells at days 8 (Figure 1E) and 14 p.i. (Supplemental 120	
Figure 2A) as well as with a higher viremia (Supplemental Figure 2B). In contrast, in infected/treated 121	
mice, viral propagation was not significantly affected at days 8- (Figure 1E) and 14- p.i. (Figure 2B 122	
and Supplemental Figure 2) upon neutrophil depletion and remained lower than in infected/non-treated 123	
mice. This suggested that viral control by 667 mAb involved other innate immunity effector cells.  124	
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Thus, neutrophils exert different antiviral effects on FrCasE-infected mice depending on 125	
immunotherapy. In animals undergoing simple infection, neutrophils participate in the control of viral 126	
propagation. Instead, in infected/treated mice, they are crucial during the immunotherapy period for 127	
generation of long-term protection against leukemia, despite their limited effect on viral propagation. 128	
 129	
NKs control viral propagation in infected/treated mice. As NKs can exert antibody-dependent cellular 130	
cytotoxicity (ADCC) activity against infected cells exposing determinants such as the retroviral Env 131	
protein (27, 39, 40), we asked whether NKs were involved in the control of viral propagation in 132	
infected/treated mice. To this end, NK cells were depleted using an anti-asialo-GM1 antibody (41–44) 133	
(Figure 2A). Contrasting to neutrophil depletion, the absence of NKs in infected/treated mice led to a 134	
significantly increased viral propagation at day 14 p.i. (Figure 2B). Next, we compared 667-mediated 135	
ADCC activity of NKs and neutrophils against infected cells using an in vivo antibody-mediated 136	
killing assay relying on the administration of 667-opsonized FrCasE-infected splenocytes in naive 137	
mice (27) (Figure 2C). Depletion of NKs, but not neutrophils, led to reduced mAb-mediated infected 138	
cell lysis (Figure 2D). Finally, as NKs are crucial for viral propagation control during the 139	
immunotherapy period, we assessed their role in the protection against leukemia in infected/treated 140	
mice. Importantly, NKs depletion drastically reduced survival of immunotreated mice (Figure 2E), 141	
indicating that antibody-mediated control of viral propagation by NKs is necessary for long-term 142	
antiviral protection. 143	
Thus, NKs are crucial for protection of infected/treated mice via efficient control of viral propagation 144	
by 667-mediated ADCC. 145	
 146	
Neutrophils differentially alter innate lymphoid cells biology in infected/treated- and infected/non-147	
treated mice. Innate lymphoid cells (ILC) are a heterogeneous population of immune cells that 148	
includes NK cells and ILC1, ILC2 and ILC3. As NK biology can be affected by neutrophils (45), we 149	
first assessed the effect of neutrophil depletion on NKs. To this end, we measured the frequency of 150	
CD3-NKp46+ cells in the spleen of mice from the different groups. CD3-NKp46+ population mostly 151	
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identifies NKs but it may also include ILC1 and a subpopulation of ILC3 cells. NK cells can be 152	
distinguished from such ILCs using the cell surface marker CD49b (46). Notably, over 95 % of CD3-153	
NKp46+ cells were CD49b+ (Supplemental Figure 3) indicating that the vast majority of CD3-NKp46+ 154	
cells in the spleen displayed a NK phenotype. As shown in Figure 3A, CD3-NKp46+ cells recruitment 155	
in spleens of both infected/non-treated and infected/treated mice at day 14 p.i. was similar and stronger 156	
than in naive mice. We also observed that neutrophils were involved in CD3-NKp46+ cells 157	
mobilization in infected/non-treated mice but neither in infected/treated- nor in naive mice (Figure 158	
3A). We next assessed the frequency of splenic ILCs, other than NKs, by quantifying CD117 and 159	
CD127 expression in the NKp46+ spleen cell population lacking the common lymphoid and myeloid 160	
lineage (Lin)-associated markers (Lin-) (47). The recruitment of those ILCs in spleens of both 161	
infected/non-treated and infected/treated mice at day 14 p.i. was not significantly different from that 162	
observed in naive mice (Figure 3B). In addition, neutrophil depletion did not significantly alter the 163	
frequency of such ILCs (Figure 3B) in any group of mice. 164	
These results show an enhanced recruitment of CD3-NKp46+ cells, which are mostly NK cells, in both 165	
infected/treated and infected/non-treated mice but these effects are neutrophil-dependent only in the 166	
latter. They also show that neutrophil depletion does not affect the frequency of splenic Lin-167	
CD117+CD127+ ILCs, in agreement with the lack of effect of anti-Ly6G-mediated-neutrophil 168	
depletion on splenic ILCs reported in other experimental settings (47). 169	
To better characterize the effect of neutrophils on splenic CD3-NKp46+ cells, we assessed their 170	
maturation by monitoring CD11b and CD27 expression at day 14 p.i. These markers identify different 171	
stages of NK maturation in mice (45). Relative to naive mice, both infected/non-treated and 172	
infected/treated mice showed similar higher frequencies of CD11b+ CD3-NKp46+ cells (including fully 173	
mature CD11b+CD27-- and semi-mature CD11b+CD27+- cells) (Figure 3C) at the expense of immature 174	
ones (CD11b-) (not shown). Moreover, depletion of neutrophils entailed a strong reduction of the 175	
frequency of CD11b+ CD3-NKp46+ cells only in infected/non-treated mice. Further characterization of 176	
CD3-NKp46+ cells indicated higher neutrophil-dependent IFN-g production in infected/treated mice 177	
but low and similar IFN-g levels in naive and infected/non-treated animals, whether the latter were 178	
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neutrophil proficient or deficient (Figure 3D). Finally, we assessed whether neutrophils affected the 179	
ADCC activity of NKs in infected/treated mice. Notably, ablation of neutrophils did not alter 667-180	
mediated ADCC activity of NK cells (Figure 3E), consistent with the lack of effect on viral 181	
propagation (Figure 1E and 2B).  182	
Thus, CD3-NKp46+ maturation is similarly enhanced in both infected/treated and infected/non-treated 183	
mice but these effects are neutrophil-dependent only in the latter. Nevertheless, neutrophils might 184	
participate in functional activation of CD3-NKp46+ cells in infected/treated animals, as our results 185	
show that neutrophils modulate their IFN-g secretion capacity in infected/treated mice. 186	
 187	
Neutrophils are crucial for inducing the humoral, but not the CD8+ T-cell, antiviral response in 188	
immunotherapy-treated mice. Since neutrophils exert no control of viral propagation during the 189	
immunotherapy period (Figure 1E and 2B) but are necessary for long-term protection of mice (Figure 190	
1D), we asked whether they could be key for the induction of vaccine-like effects. 191	
We first addressed cellular adaptive immunity by assaying the primary virus-specific CD8+ T-cell 192	
response in infected/non-treated and infected/treated mice at its peak (i.e. 14 days p.i.) (27) with or 193	
without neutrophils depletion. Consistent with our previous work, infected/treated mice showed an 194	
increased virus-specific CD8+ T-cell response relative to infected/non-treated mice. In neither case the 195	
frequency of virus-specific CD8+ T cells was altered by neutrophil depletion (Figure 4A). Similarly, 196	
neither case showed any difference in the frequency of CD8+ T cells expressing IFN-g (Figure 4B). 197	
These data ruled out a major role for neutrophils in the 667 mAb-induced anti-viral CD8+ T-cell 198	
response. 199	
Next, we addressed humoral immunity in infected/non-treated and infected/treated mice, depleted or 200	
not in neutrophils. To achieve this, anti-FrCasE serum immunoglobulins (Ig) from mice of the 201	
different groups were assayed by ELISA. Virus-specific IgM titers were assayed at 14 days p.i.  (i.e. at 202	
the peak of the IgM response upon FrCasE infection and 667 treatment, Supplemental Figure 4) and 203	
were not significantly different between infected/non-treated and infected/treated mice (Figure 5A). 204	
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Interestingly, neutrophils depletion did not alter virus-specific IgM titers in either infected/non-treated 205	
or infected/treated mice (Figure 5A). In agreement with published studies in other experimental 206	
settings, the absence of neutrophils did not affect the levels of IgM (48). On the contrary, and 207	
consistent with our previous work (27), infected/treated mice displayed a much higher level of anti-208	
FrCasE IgGs than infected/non-treated animals (Figure 5B), with a peak (700 µg/ml) by day 68 post-209	
infection and a still high level (100 µg/ml) at the end of the experiment. Interestingly, in the absence of 210	
neutrophils, serum concentration of antiviral IgGs dramatically decreased in infected/treated mice 211	
(Figure 5B and Supplemental Figure 5). In contrast, neutrophils showed no role in the regulation of the 212	
poor non-protective antibody response elicited in infected/non-treated mice (Figure 5B). Importantly, 213	
high anti-FrCasE IgG seric levels correlated with longer survival times, supporting a role for the high 214	
humoral antiviral response in protection against disease  (Figure 5C). To further characterize the long-215	
term virus-specific humoral response, we tested whether infected/treated mice, depleted or not in 216	
neutrophils, could respond to a virus challenge performed 3 months after the first infection (i.e. a time 217	
point at which the primary humoral response has strongly declined). Infected/treated mice, depleted or 218	
not in neutrophils, were inoculated with FrCasE and serum samples were collected 1 week later to 219	
assay the generation of endogenous anti-FrCasE antibodies. In the presence of neutrophils, 3 out of 5 220	
infected/treated mice showed an increase in the virus-specific humoral response (Figure 5 D) while, in 221	
the absence of neutrophils, none of the infected/treated mice responded to the viral challenge. 222	
Altogether, these results show that neutrophil depletion at early time points after infection and 223	
treatment affects humoral immunity with an effect on both primary and memory virus-specific B-cell 224	
responses.  225	
As marginal zone (MZ) B cells are known to contribute to the mounting of antibody responses (49, 50) 226	
and their function might be modulated by neutrophils (51), we next addressed the frequencies of 227	
splenic MZ (CD21highIgMhigh CD19+ cells)- and follicular (FO)  (CD23+IgMlow CD19+ cells) B 228	
cells. MZ B-cells frequency was enhanced in a neutrophil-dependent manner in infected/treated mice 229	
but unchanged in infected/non-treated animals relative to naive mice (Figure 6A). In contrast, the 230	
frequency of FO B cells was significantly enhanced in infected/treated mice relative to naive mice, 231	
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with however no role for neutrophils (Figure 6B). Interestingly, consistent with a role of MZ B cells in 232	
the generation of plasma cells (49), the higher frequency of splenic MZ B cells at day 14 p.i. in 233	
infected/treated mice was associated with a higher frequency of CD138+ plasma cells in bone-marrow 234	
(BM), as compared to infected/non-treated animals. This effect was neutrophil-dependent (Figure 6C). 235	
Finally, histological analyses of spleens of infected mice at 14 days p.i. revealed larger germinal 236	
centers (GC, defined by staining of MZ CD169+ macrophages and B220+ cells) in infected/treated 237	
versus infected/non-treated mice (Figure 6D). In agreement with a role of neutrophils in the 238	
enhancement of the humoral response, neutrophil depletion in infected/treated mice led to smaller GCs 239	
(Figure 6D).  240	
Thus, neutrophils are essential for the vaccine-like effects induced by the 667 immunotherapy through 241	
the stimulation of the humoral, but not the CD8+ T-cell, antiviral response. This effect is associated 242	
with a neutrophil-dependent increase in both splenic MZ B cells and BM plasma cells. 243	
 244	
Neutrophils are differently activated in infected/-treated- and -non-treated mice. Finally, we addressed 245	
the functional activation of splenic neutrophils in infected mice with or without 667 immmunotherapy 246	
at day 8 p.i. by monitoring cell surface activation markers and quantifying various cytokine mRNA 247	
and protein levels. In infected/treated- and infected/non-treated mice, splenic neutrophils were 248	
similarly activated, as deduced from CD62L shedding and increased expression of CD11b (Figure 249	
7A). However, neutrophils from infected/treated mice showed a significantly stronger expression of 250	
two cytokines involved in B-cell activation, B cell-activating factor (BAFF) and lymphotoxin a 251	
(LTa), compared to infected/non-treated animals (Figure 7B), suggesting a role for the therapeutic 252	
mAb in the functional activation of neutrophils. Splenic neutrophils sorted from infected/treated mice 253	
also showed a trend for higher secretion capacity of BAFF and LTa, as compared to infected/non-254	
treated mice neutrophils, even though such a trend did not reach statistical significance. To further 255	
assess whether mAb-triggering (through FcgR cross-linking) could enhance BAFF and LTa release by 256	
neutrophils, we isolated BM neutrophils from naive mice and stimulated them for 24 h in plates coated 257	
with the 667 mAb. Experiments were conducted in the presence or the absence of the pro-258	
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inflammatory cytokine IFN-g to assess the extent to which inflammatory conditions could synergize 259	
with 667 mAb-triggering. Interestingly, in the presence of IFN-g, 667 mAb triggering led to a 260	
significantly increased release of BAFF and LTa by neutrophils (Figure 7C). 261	
In summary, FrCasE infection activates neutrophils independently of immunotherapy. However, the 262	
activation state significantly differs between the two groups of animals, notably with a significantly 263	
stronger expression of LTa and BAFF in immunotherapy-treated mice. In addition, inflammatory 264	
conditions synergize with mAb-mediated activation of neutrophils leading to an enhanced release of 265	
BAFF and LTa.  266	267	
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DISCUSSION 268	
 269	
We have previously shown that antiviral mAb-based therapies can induce life-long protective 270	
immunity. This finding potentially has important therapeutic implications, as evidence suggests that it 271	
may also apply to diverse severe human viral diseases (10, 14). A paramount task is now to identify 272	
the mechanisms at the origin of the mAb-induced vaccine-like effects and exploit them for more 273	
efficient mAb-based treatment of patients.  274	
Here, we report that neutrophils are essential during the immunotherapy period for long-term survival 275	
of FrCasE-infected mice, not because they control viral propagation but because they are crucial for 276	
inducing a protective humoral response without an effect on the CD8+ T-cell response. In contrast, we 277	
show that, upon 667 mAb treatment, NKs are crucial for the elimination of infected cells by 667-278	
mediated ADCC activity and are necessary for long-term survival of infected/treated mice. Thus, our 279	
work indicates that both innate effector cells have distinct but complementary roles in the protection of 280	
infected mice by mAb; NKs have an early and predominant role in the control of viral spread while 281	
neutrophils are essential for the emergence of a potent host antiviral humoral response. Our findings 282	
contrast with the current view of neutrophils usually considered as simple frontline agents against 283	
invading pathogens and highlight the hitherto unreported role of neutrophils as key cells in the 284	
modulation of adaptive antiviral immunity upon mAb treatment. 285	
Our data indicate that survival of infected/treated mice depends on an efficient anti-FrCasE humoral 286	
response. Infected/treated mice show neutrophil-dependent (i) increased frequency of MZ B cells, (ii) 287	
enhanced formation of GCs, (iii) increased plasma cell generation and (iv) enhanced production of 288	
antiviral IgGs. Interestingly, the absence of neutrophils during the immunotherapy period in infected 289	
mice also leads to impaired development of secondary humoral responses upon viral challenge. 290	
Overall our data suggest that neutrophils are essential for antiviral protection due to their B-cell-helper 291	
activity. Similarly, such a helper function has already been documented under homeostatic conditions 292	
(51), in autoimmunity disease-prone mice (52), during emergency granulopoiesis (53) and in bacterial 293	
infection (54). Importantly, our findings show that the acquisition of B-cell helper functions in 294	
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infected mice is dependent on immunotherapy, as no modulation of the anti-FrCasE humoral response 295	
was detected in infected/non-treated mice upon neutrophil depletion.  296	
Though not excluding the role of other factors, our study suggests potential roles for BAFF and LTa 297	
in this B-cell helper function. As concerns BAFF, it is interesting to note that its secretion by splenic 298	
neutrophils can contribute to the activation of splenic MZ B cells and the acceleration of plasma cell 299	
generation (51, 55). Moreover, BAFF administration to mice increases both the frequency of MZ B 300	
cells and antibody production (56, 57) and constitutes a signal for both MZ B cell survival and 301	
differentiation into plasmablasts (47, 58–61) . Together with the fact that MZ B cells can favor the 302	
generation of plasma cells upon microbial infection (49), it is reasonable to speculate that BAFF 303	
induction in neutrophils of infected/treated mice may also favor the MZ B cell response and the 304	
subsequent generation of plasma cells. Interestingly, in agreement with our in vitro results showing 305	
enhanced BAFF release by neutrophils upon combination of IFN-g stimulation and FcgR cross-link 306	
(Figure 7C), different pro-inflammatory stimuli, including ICs, have been shown to act as 307	
secretagogues and to synergize with IFN-g to enhance BAFF secretion by human neutrophils (62). 308	
Moreover, neutrophil depletion in autoimmunity-prone mice led to a reduction of auto-antibodies titers 309	
that correlated with decreased serum levels of IFN-g and BAFF (52). Thus, it can reasonably be 310	
hypothesized that inflammatory conditions synergize with ICs formed after 667 mAb-treatment of 311	
FrCasE-infected mice to enhance BAFF release by neutrophils. 312	
Although not formally shown, our data suggest that LTa release by neutrophils might play a role in 313	
the enhancement of the antiviral humoral response in infected/treated mice. LTa is involved in the 314	
formation of secondary lymphoid organs, it is expressed by lymphocytes and mediates a large variety 315	
of inflammatory and antiviral responses. It has also been reported to play a role in the development of 316	
GC formation and to be required for IgG responses (63–65). Here, we show that this cytokine is 317	
expressed and released by neutrophils upon mAb treatment of infected mice. Interestingly, although 318	
LTa is not known to be expressed by neutrophils, it has been proposed that non-lymphocytic murine 319	
splenic cells are able to produce it (66). We also report that FcgR cross-linking by immobilized 667 320	
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mAb synergizes with IFN-g to enhance LTa release by neutrophils. This suggests that, similarly to 321	
BAFF, inflammatory conditions and mAb-triggering might lead to increased LTa secretion by 322	
neutrophils. Further studies will be required to address whether BAFF and LTa combine their actions 323	
to stimulate the antiviral humoral response upon mAb immunotherapy. Finally, as IFN-g potentiates 324	
both BAFF and LTa release, it will also be important to assess whether and how neutrophil-dependent 325	
IFN-g production by NKs in infected/treated mice contributes to the stimulation of antibody responses, 326	
as this cytokine affects class-switching and long-term maintenance of neutralizing antibody titers in 327	
retrovirally-infected mice (34) and humoral autoimmunity in humans (67).  328	
Identifying neutrophils as key players in the induction of protective immunity by antiviral mAbs has 329	
important therapeutic implications for several reasons. First, if combination therapies are considered, it 330	
will be of utmost importance that the agent(s) co-administered with the passive immunotherapy do not 331	
alter neutrophil functions and counts to avoid inhibiting efficient antiviral humoral immune responses. 332	
Second, in pathological situations leading to neutropenia and/or impaired neutrophils functions, such 333	
as certain viral infections (68, 69) and/or drug-induced neutropenia (70), it will be essential to restore 334	
them. This could, for example, be achieved through administration of granulocyte colony-stimulating 335	
factor (G-CSF) a cytokine already used in the clinic to treat neutropenic patients. Interestingly, this 336	
cytokine might also be used in combination with treatments aiming at enhancing the generation of 337	
functional neutrophils (70). Furthermore, beyond stimulating neutrophil activation and/or 338	
mobilization, G-CSF enhances neutrophil BAFF-secretion capacity and thereby their ability to 339	
stimulate B cells (71). Similarly, reduction of viral load by antiretroviral therapies also permits partial 340	
restoration of the impaired functions of neutrophils observed in HIV-infected patients (68). 341	
Interestingly, neutrophils have been shown to mediate immunosuppression via the PD-L1/PD-1 342	
pathway in HIV-infected patients (72). Antiviral passive immunotherapies might therefore benefit 343	
from combination with the administration of mAbs targeting this immune checkpoint. Finally, 344	
alternative approaches, such as engineering the Fc fragment of antiviral mAbs, merit consideration. 345	
Increasing their affinity for the FcgRs expressed by neutrophils might, at first, allow superior antibody-346	
mediated phagocytosis, as recently reported in the case the Fc-modified VR01 anti-HIV mAb (73). 347	
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This could then alter cell signaling and cytokine/chemokines production to ultimately lead to more 348	
effective adaptive immune responses. Thus, stimulating neutrophil activity, restoring their impaired 349	
functions and/or counteracting their immunosuppressive actions should improve the vaccine-like 350	
effects of antiviral mAb-based immunotherapies. This might also apply to cancer treatment as 351	
enhancement of antitumoral immune responses has also been observed in mAb-based anticancer 352	
immunotherapies. This is all the more important to take into consideration as neutrophils have been 353	
shown to play a role in the therapeutic activity of anticancer mAb (74–78). 354	
  355	
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METHODS 356	
Ethical statement. Mice were bred and maintained under conventional, pathogen-free facilities at the 357	
Institut de Génétique Moléculaire de Montpellier. All experimental procedures were performed in 358	
accordance with the French national animal care guidelines (CEEA-LR-12146 approval). 359	
 360	
Viral stocks. FrCasE viral stocks were produced, assayed and stored as described previously (27). 361	
 362	
Viral infection, immunotherapy and mice follow-up. Eight day-old 129/Sv/Ev mice were infected 363	
intraperitoneally (i.p.) with 50 µl of a virus suspension containing 50,000 ffu (focus-forming units) 364	
and treated, or not, with 30 µg of 667 mAb 1 hour post-infection (p.i.) and on days 2 and 5 p.i. by i.p. 365	
administration. Mice were examined at regular intervals for clinical signs of erythroleukemia 366	
(reduction of hematocrits). They were euthanized when their hematocrits reached 35% (experimental 367	
endpoint). 368	
 369	
Flow cytometry. Spleen single-cell suspensions were obtained by mechanical dissociation of the 370	
organs in PBS. Bone marrow (BM) cell suspensions were obtained by dissection and PBS-flushing of 371	
tibias and femurs. Cells were stained at 4°C using fluorochrome-conjugated antibodies to: CD3e (145-372	
2C11), CD4 (RM4-5), CD8 (Ly2, 53-6.7), CD11b (M1/70), CD11c (HL3), CD19 (1D3), CD21/35 373	
(eBio8d9), CD23 (B3B4), CD27 (LG3A10), CD45.2 (104), CD45R/B220 (RA3-6B2), CD49b (DX5), 374	
CD62L (Ly22, MEL-14), CD117 (2B8), CD127 (SB/199), CD138 (281-2), F4/80 (BM8), Gr1 (RB6-375	
8C5), IFN-g (XMG1.2), IgM (eB121-15F9), Ly6G (1A8), lineage (Ter119; Gr1; CD45R/B220; 376	
CD11c; F4/80; CD3e), NKp46 (29A1.4) (BD Bioscience, eBioscience or BioLegend). FrCasE-377	
infected cells were assayed using an anti-Gag mAb (H34) (35) labelled with Alexa Fluor 647. Forward 378	
scatter area and forward scatter time-of-flight, as well as side scatter, were used to remove doublets 379	
from flow cytometry analyses. Cells were analyzed on FACSCanto II flow cytometer (BD Bioscience) 380	
and the data were analyzed using the FlowJo software (Tree Star). 381	
 382	
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ELISA of anti-FrCasE antibodies. Plasma anti-FrCasE immunoglobulins were assayed by ELISA as 383	
already described (26, 27). Peroxidase-conjugated anti-mouse IgG or IgM rabbit antisera (Serotec) 384	
were used as secondary antibodies. 385	
Virus challenge experiments. Infected/treated mice, depleted or not in neutrophils, were injected i.v. 386	
with 300 µl of a 5 x 10
4 FFU/ml FrCasE suspension mixed to 2 x 10
6  FrCasE-infected splenocytes 3 387	
months after the first infection. Blood samples were collected 1 week post-challenge to assay 388	
endogenous anti-FrCasE IgG concentrations by ELISA. 389	
In vivo depletion of Ly6G+ and NK cells. Neutrophils were depleted by administering a rat anti-Ly6G 390	
antibody (1A8; BioXcell), (37, 38) injected i.p. at different time-points (150 µg/injection) or isotype 391	
control rat IgG (2A3; BioXcell).  Neutrophils depletion was monitored by flow cytometry analysis of 392	
Gr1high and CD11b+ cells. NKs were depleted using the anti-asialo GM1 antibody (Wako Pure 393	
Chemical Industries, Ltd), injected i.p. at different time-points (50 µl/injection). This antibody has 394	
been used to study the in vivo functions of NKs in mouse strains lacking the NK1.1 allotype, which is 395	
a feature of 129 Sv/Ev mice (42).  396	
 397	
In vivo cytolysis activity. Experiments were conducted as described in (27, 79). Briefly, red blood cell-398	
free splenocytes were recovered from 10 day-old FrCasE-infected-, or non-infected, pups. Splenocytes 399	
from non-infected mice were labelled with the vital dye carboxy-fluorescein succinimidyl ester 400	
(CFSE; Molecular Probes) at a concentration of 0.5 μM (CFSElow cells). Splenocytes from infected 401	
mice were labelled with 5 μM CFSE (CFSEhigh cells) and pre-incubated, or not, with the 667 mAb (the 402	
absence of 667 allows to quantify spontaneous cell death). Both cell populations were mixed at a 1:1 403	
ratio before retrorbital administration to recipient mice. Cytolysis activity against infected splenocytes 404	
was calculated from the ratio of CFSElow/CFSEhigh cells in spleen assayed by flow cytometry 5 hours 405	
later. To assess the contribution of NKs and neutrophils to antibody-mediated cytolysis, 50 µl of the 406	
anti-asialo GM1 or 200 µg of the anti-Ly6G 1A8 mAb were administered 1 day prior to the assay. 407	
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Flow cytometry assay of CD8+ T cells specific for FrCasE-infected cells. Splenocytes were labelled 409	
with both an APC-conjugated anti-CD8+ T cell antibody and a PE-conjugated MHC class I H-2Db 410	
tetramer (Beckman Coulter) displaying the immunodominant Friend virus GagL epitope (27) (80) (Db-411	
GagL tetramers) as previously described (27). 412	
 413	
Assay of IFN-g production. 106 splenocytes were incubated at 37°C for 5 hours in 12-well plates in 414	
500 µl of RPMI culture medium containing phorbol 12-myristate 13-acetate (50 ng/ml) and ionomycin 415	
(500 ng/ml) in the presence of brefeldin A (10 µg/ml; Sigma-Aldrich). IFN-g production was flow 416	
cytometry-assayed using the intracellular Cytofix/Cytoperm Fixation/Permeabilization staining kit 417	
(Becton Dickinson). 418	
 419	
Histological analyses. Spleens from infected/non-treated- and infected/treated mice (depleted or not in 420	
neutrophils) were recovered at day 14 p.i. and prepared as previously described (81). Briefly, spleens 421	
were initially fixed at 4°C overnight with a PLP (Paraformaldehyde-lysine-periodate) solution and 422	
then embedded in 4% low temperature-gelling agarose (type VII-1; Sigma-Aldrich) prepared in PBS 423	
(Phosphate Buffered Saline). 300 µm slices were cut with a vibratome (VT 1000S; Leica) in a bath of 424	
ice-cold PBS. Sections of tissues were submerged in PBS and transferred to 0.4 µm organotypic 425	
culture inserts (Millicell; Millipore) for staining with an anti-B220 (RA3-6B2, Becton Dickinson) and 426	
an anti-CD169 antibody (MOMA-1, Biorad) at 37°C for 20 minutes. The images were captured using 427	
a Leica SP8-UV confocal scanning microscope. 428	
 429	
RT-qPCR quantification of gene expression. Single-cell suspensions of splenocytes were prepared 430	
from naive, infected/non-treated and infected/treated mice 8 days p.i. and immunotherapy. Neutrophils 431	
(CD11b+Ly6Ghigh expression) were sorted (>98% pure) using a BD Biosciences FACSAria device. 432	
RNA was extracted from 1-2 x 106 sorted neutrophils using the RNeasy micro kit (Qiagen). RNA 433	
quality and integrity were verified using the Agilent 2100 bioanalyzer. cDNAs were synthesized using 434	
the RT2 First Strand Kit (Qiagen). All quantitative PCRs were performed following protocols 435	
optimized for the RT2 quantitative Profiler PCR array using SYBR Green mix (Qiagen) and 436	
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LightCycler 480 II machine (Roche). All data were normalized to b-actin. Results were expressed as 437	
fold increases with respect to naive cells using the ΔΔCt method.  438	
 439	
BAFF and LTa protein release quantification. Soluble BAFF and LTa from cell-free supernatants of 440	
cultured neutrophils were assayed using BAFF (R&D Systems) and LTa ELISA (NeoBiotech), 441	
respectively. Supernatants were collected from sorted splenic neutrophils (from naive, infected/non-442	
treated and infected/treated mice at 8 days p.i. and immunotherapy) cultured in 96-well plates at a 443	
density of 2x105 cells/well for 24 h. Alternatively, neutrophils were isolated from naive mice BM 444	
using a magnetic-based cell-sorting (MACS) neutrophil isolation kit (>95% purity; Miltenyi Biotec) 445	
and cultured for 24 h in 667mAb-coated 24-well plates at a density of 2 × 106 cells in 500 µl of 446	
medium, in the presence or in the absence of IFN-g (100 µg/mL). 667 mAb-non coated plates were 447	
used as controls. G-CSF (R&D Systems) was added at a concentration of 10 ng/ml to neutrophil 448	
cultures to maintain cell viability 449	
 450	
Statistical analyses. Statistical analyses were performed using GraphPad Prism 5 (GraphPad 451	
Software). Data were expressed as means +/- SEM and statistical significance was established using a 452	
parametric one-way ANOVA test with a Bonferroni correction for multiple comparisons or unpaired 453	
Student’s t tests	when two groups were compared. p values lower than 0.05 were considered as 454	
statistically significant.  455	
 456	
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FIGURES  671	
Figure 1. Antiviral effects of neutrophils. (A) Experimental scheme. Upper part: 8 day-old pups were infected 672	
and treated with the 667 mAb as indicated. Lower part: mice were treated as indicated with the anti-Ly6G 1A8 673	
mAb or the isotype control 2A3 mAb in neutrophil depletion experiments. (B-C) Neutrophil recruitment and 674	
infected cells rate in spleen. Splenocytes from naive, infected/non-treated (I/NT) and infected/treated (I/T) mice 675	
were analyzed by flow cytometry on day 8 p.i. for (i) neutrophil recruitment (% of Ly6G+ cells) and (ii) for 676	
retroviral positivity of splenocytes (% of Gag+ cells) gated in the CD45.2+ population. The data presented 677	
correspond to 5 independent experiments with at least 15 mice per group. (D) Mouse survival. Naive, I/NT and 678	
I/T mice were treated with either the anti-neutrophil- (1A8) or the control (2A3) mAb as indicated in (A) and 679	
followed up for leukemic death. The data represent 2 independent experiments with 6-9 mice per group. (E) 680	
Infected cells rate upon neutrophil depletion. Neutrophils of naive, I/NT and I/T mice were depleted, or not, as 681	
indicated in (A) and infected splenocytes were assayed as in (C) on day 8 p.i. The data represent 4 independent 682	
experiments with 9-15 mice per group. Data are expressed as means +/- SEM. Statistical significance was 683	
established using a parametric one-way ANOVA test with a Bonferroni correction. (*p < 0.05; **p < 684	
0.01; ***p < 0.001). 685	
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Figure 2. Antibody-mediated control of viral propagation by NKs. (A) Experimental scheme. Mice were 687	
infected and mAb-treated as in Fig 1A. Upper part: infected/treated mice were treated as indicated with the anti-688	
Ly6G 1A8 mAb or the isotype control 2A3 mAb to deplete neutrophils. Lower part: infected/treated mice were 689	
treated as indicated with the anti-asialo-GM1 antibody to deplete NKs. (B) Effect of neutrophils or NKs 690	
depletion in viral spread in infected/treated mice. Percentage of infected cells at day 14 p.i in the spleen of 691	
naive-, I/NT- and I/T mice, depleted or not in neutrophils or NKs assessed as in Fig 1C. The data represent 3 692	
independent experiments with at least 8 mice per group.Data are expressed as means +/- SEM. (*p<0,05, **p 693	
< 0.01,***p<0,001). (C-D) In vivo cytolysis activity of 667 in naive mice after depletion of neutrophils or NKs. 694	
Splenocytes from non-infected mice (Sp) were labelled using 0.5 μM  of the vital dye CFSE (CFSElow cells; M1) 695	
and mixed at a 1:1 ratio with splenocytes from infected mice (Infected-Sp) labelled using 5 μM CFSE (CFSEhigh 696	
cells; M2) and pre-incubated, or not, with the 667 mAb. Mixed cell populations were administered to naive mice 697	
1 day after depletion of either neutrophils or NKs with the 1A8 mAb or the anti-asialo-GM1 antibody, 698	
respectively. Cytolysis was quantified 5 hours later as described in Methods section. The data are presented as 699	
mean ± SEM of 2 independent experiments with at least 8 mice per group. Statistical significance was 700	
established using a parametric one-way ANOVA test with a Bonferroni correction (panels B and D). 701	
(E) Effect of NKs depletion in the survival of infected/treated mice. I/T, NKs-depleted or not as indicated in (A) 702	
were followed up for leukemic death. The data represent 2 independent experiments with 7 mice per group. 703	
Statistical significance was established using an unpaired Student’s test. 704	
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Figure 3. Effects of neutrophil depletion on innate lymphoid cells recruitment and biology. (A-D) 705	
Neutrophils of naive, I/NT and I/T mice were depleted, or not, as indicated in Figure 1A and ILC in the spleen 706	
were assayed 14 days p.i. by flow cytometry. (A) Frequency of CD3-NKp46+ cells in the CD45.2+ leukocytic 707	
population. (B) Frequency of CD117+/CD127+ cells in the Lin-NKp46+ population. (C) Maturation (CD11b+ 708	
cells) and (D) expression of IFN-g  in the CD3-NKp46+ population. (E) In vivo cytolysis activity of 667 in 709	
infected/treated mice after depletion of neutrophils. The 1A8, or the 2A3 isotype control mAb, were 710	
administered to I/T mice and 667 ADCC activity was quantified at 30 days p.i. as in Fig 2C-2D. The data 711	
represent at least 2 independent experiments. Data are expressed as means +/- SEM. Statistical 712	
significance was established using a parametric one-way ANOVA test with a Bonferroni correction 713	
(*p < 0.05; **p < 0.01; ***p < 0.001).  714	
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Figure 4. Assay of FrCasE-specific CD8+ T cells in the presence and absence of neutrophils.  Neutrophils of 715	
naive, I/NT and I/T mice were depleted, or not, as indicated in (A). Frequency of FrCasE-specific CD8+ T cells. 716	
Spleen cells were isolated at day 14 p.i. and the frequency of virus-specific CD8+ T cells in the total CD8+ T-717	
cells population was assayed by flow cytometry using the H2Db-GagL MHC tetramer. The data represent 4 718	
independent experiments with at least 11 mice per group. (B) Expression of IFN-g by CD8+ T cells. Splenic 719	
CD8+ T cells were flow cytometry-analyzed for the expression of IFN-g. The data presented represent 3 720	
independent experiments with at least 7 mice per group. Data are expressed as means +/- SEM. Statistical 721	
significance was established using a parametric one-way ANOVA test with a Bonferroni correction 722	
(*p< 0,05).  723	
 724	
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Figure 5. Enhancement of the humoral antiviral response by neutrophils. Neutrophils of naive, I/NT and I/T 725	
mice were depleted, or not, as indicated in Figure 1A. (A, B) Serum concentration of FrCasE-specific Igs. (A) 726	
Seric FrCasE-specific IgM levels were assayed by ELISA at 14 days p.i.  The data represent 2 independent 727	
experiments with 8-11 mice per group (for I/NT and I/T mice) and 3 to 6 mice per group (for naive mice). (B) 728	
Seric FrCasE-specific IgG concentration was assayed by ELISA at the indicated times. The data represent 2 729	
independent experiments with 7-9 mice per group. Data are expressed as means +/- SEM. Statistical 730	
significance was established using a parametric one-way ANOVA test with a Bonferroni correction 731	
(*p < 0.05; **p < 0.01; ***p < 0.001). (C) Correlation between serum anti-FrCasE IgG levels (evaluated as the 732	
area under the curve; AUC) and survival times, analyzed using the Pearson correlation test. AUC was evaluated 733	
until the last time point at which all mice were still alive (day 68 p.i). All infected/non-treated- (n = 8), 734	
infected/treated- (n = 9) mice, depleted or not in neutrophils (n = 9 and n = 7, respectively), showed in Fig 1D 735	
were evaluated for such a correlation. (D) FrCasE-specific secondary humoral response. Seric FrCasE-specific 736	
IgG levels in I/T mice (depleted or not in neutrophils) were assayed by ELISA before and 1 week after a viral 737	
challenge performed at day 93 p.i. The data represent 2 independent experiments with 5 mice per group. 738	
Statistical significance was established using a paired Student’s t test. 739	
 740	
 741	
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Figure 6. Effects of neutrophil depletion on B-cell responses. (A-D) Neutrophils of naive, I/NT and I/T mice 742	
were depleted, or not, as indicated in Figure 1A. (A-B)  Frequency of MZ and follicular (FO) B cells. Spleen 743	
cells were isolated at day 14 p.i. and flow cytometry-analyzed for the frequency of MZ (CD21highIgMhigh) (A) 744	
and FO (CD23+IgMlow) (B) CD19+ B cells. (C) Frequency of plasma cells. BM cells were isolated at day 14 p.i. 745	
and flow cytometry-analyzed for the frequency of CD138+ (CD19+) B cells. The data represent 5 independent 746	
experiments with 7-12 mice per group for naive mice and 17-21 per group for I/NT and I/T mice.  Data are 747	
expressed as means +/- SEM. Statistical significance was established using a parametric one-way 748	
ANOVA test with a Bonferroni correction. (*p < 0.05; **p < 0.01; ***p < 0.001). (D) Histological analyses 749	
of spleen sections. Immunolabelling of B cells (B220+) and macrophages of the MZ (CD169+) was performed in 750	
sections from spleens of infected/non-treated and infected/treated mice (depleted or not in neutrophils) recovered 751	
at 14 days p.i. to visualize germinal centers. The images are representative of four separate mice for each 752	
experimental condition. Scale bar 200 µm. 753	
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Figure 7. Activation of splenic and BM-isolated neutrophils. (A) Expression of CD11b and CD62L. Spleen 754	
cells from naive, I/NT and I/T mice were isolated at day 8 p.i. and flow cytometry-analyzed for assaying cell 755	
surface expression of CD11b and CD62L. The data represent 5 independent experiments with at least 18 mice per 756	
group. Data are expressed as means +/- SEM. (B) Expression and protein release of BAFF and LTa by 757	
neutrophils. Neutrophils from naive, I/NT and I/T mice were sorted from the spleen at day 8 p.i. and assessed for 758	
cytokine expression or protein release. Cytokine expression (left) was assessed by RT-qPCR normalized to b-actin. 759	
The data show fold changes in cytokine expression by neutrophils from I/NT and I/T mice as compared to naive 760	
mice and are representative of 3 independent experiments with 8-10 mice per group. Protein release (right) was 761	
assessed by ELISA in supernatants of sorted neutrophils cultured at a density of 105 cells/well for 24 h. The data 762	
show BAFF and LTa release by neutrophils from I/NT and I/T and are representative of 3 independent 763	
experiments with 8-10 mice per group. The dashed line represents the level of BAFF released by neutrophils 764	
sorted from naive mice. No LTa release was detected from neutrophils sorted from naive mice. . (C) BAFF and 765	
LTa release by BM-isolated neutrophils. BAFF and LTa release was assessed by ELISA in supernatants of 766	
neutrophils isolated from BM of naive mice (>95% purity) and cultured for 24 h in 667-mAb coated 24-well plates 767	
at a density of 2 × 106 cells in 500 µl of medium. Experiments were done in the presence and in the absence of the 768	
pro-inflammatory cytokine IFN-g (100 µg/ml). 667 mAb non-coated plates were used as control. The data 769	
represent 4 independent experiments. Data are expressed as means +/- SEM. Statistical significance was 770	
established using a parametric one-way ANOVA test with a Bonferroni correction (panels A and C) or a 771	
paired Student’s t test (panel B). (*p < 0.05; **p < 0.01; ***p < 0.001). 772	
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